Systemic Sclerosis (SSc) is a chronic autoimmune disease, characterized by immune system activation, vascular abnormalities and uncontrolled fibrotic response in the skin and internal organs [1]. The microvascular abnormalities have a significant part in the early pathogenesis of the disease [2] and carry a significant impact on the prognosis, comparable to that of interstitial lung disease (ILD) [3–5]. While Raynaud's phenomenon (RP) is the first vascular manifestation [6], SSc vasculopathy can also affect internal organs [7], causing tissue ischemia, cellular homing, fibrosis, defective angiogenesis, and consequent malfunctioning [8–10].
